Acquisition by Hui Liu of 98085 shares of Merus BV at 7.86 subject to Rule 16b-3
| MRUS Stock | USD 52.99 0.19 0.36% |
Slightly above 55% of Merus BV's investor base is interested to short. The analysis of overall sentiment of trading Merus BV stock suggests that many investors are impartial at this time. Merus BV's investing sentiment can be driven by a variety of factors including economic data, Merus BV's earnings reports, geopolitical events, and overall market trends.
Filed transaction by Merus BV Officer: Evp, Cbo & Head Of Merus Us. Grant, award or other acquisition pursuant to Rule 16b-3(d)
Read at macroaxis.com
Merus BV Fundamental Analysis
We analyze Merus BV's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Merus BV using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Merus BV based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Gross Profit
Gross Profit Comparative Analysis
Merus BV is currently under evaluation in gross profit category among its peers. Gross Profit is the most basic measure of business operational efficiency. It is simply the difference between sales revenue and the cost associated with making a product or providing a service. It is calculated before deducting administrative expenses, taxes, and interest payments.
Merus BV Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Merus BV stock to make a market-neutral strategy. Peer analysis of Merus BV could also be used in its relative valuation, which is a method of valuing Merus BV by comparing valuation metrics with similar companies.
Peers
Merus BV Related Equities
| ANEB | Anebulo Pharmaceuticals | 2.82 | ||||
| ADAG | Adagene | 1.05 | ||||
| PTGX | Protagonist Therapeutics | 0.85 | ||||
| KRON | Kronos Bio | 0.00 | ||||
| CRNX | Crinetics Pharmaceuticals | 0.10 | ||||
| PCVX | Vaxcyte | 0.91 | ||||
| KURA | Kura Oncology | 1.05 | ||||
| REPL | Replimune | 1.37 | ||||
| LRMR | Larimar Therapeutics | 1.62 | ||||
| LYEL | Lyell Immunopharma | 1.97 | ||||
| MLYS | Mineralys Therapeutics, | 2.07 | ||||
| INBX | Inhibrx Biosciences, | 2.43 | ||||
| SNDX | Syndax Pharmaceuticals | 2.80 | ||||
| ANAB | AnaptysBio | 3.89 | ||||
| ACRV | Acrivon Therapeutics, | 8.40 | ||||
| STRO | Sutro Biopharma | 8.75 |
Additional Tools for Merus Stock Analysis
When running Merus BV's price analysis, check to measure Merus BV's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Merus BV is operating at the current time. Most of Merus BV's value examination focuses on studying past and present price action to predict the probability of Merus BV's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Merus BV's price. Additionally, you may evaluate how the addition of Merus BV to your portfolios can decrease your overall portfolio volatility.